Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R)

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 3, 2009, Pages 1004-1008

  Emmitte, Kyle A ^a   Wilson, Brian J ^a   Baum, Erich W ^a   Emerson, Holly K ^a   Kuntz, Kevin W ^a   Nailor, Kristen E ^a   Salovich, James M ^a   Smith, Stephon C ^a   Cheung, Mui ^a   Gerding, Roseanne M ^a   Stevens, Kirk L ^a   Uehling, David E ^a   Mook Jr , Robert A ^a   Moorthy, Ganesh S ^a   Dickerson, Scott H ^a   Hassell, Anne M ^a   Anthony Leesnitzer, M ^a   Shewchuk, Lisa M ^a   Groy, Arthur ^a   Rowand, Jason L ^a   Anderson, Kelly ^a   Atkins, Charity L ^a   Yang, Jingsong ^a   Sabbatini, Peter ^a   Kumar, Rakesh ^a   more..

^a GLAXOSMITHKLINE   (United States)

Author keywords

Cancer; Imidazo 1,2 a pyridine; Insulin receptor; Insulin like growth factor 1 receptor; Kinase inhibitor

Indexed keywords

IMIDAZO[1,2 A]PYRIDINE DERIVATIVE; RECEPTOR BLOCKING AGENT; SOMATOMEDIN C RECEPTOR; SOMATOMEDIN C RECEPTOR INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CHEMICAL REACTION; CONFORMATIONAL TRANSITION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; RAT; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANILINE COMPOUNDS; ANIMALS; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MODELS, CHEMICAL; MOLECULAR CONFORMATION; PYRIDINES; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN;

MUS;

EID: 58549088976     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.11.058     Document Type: Article

References (48)

1. LeRoitho D., and Roberts Jr. C.T. Cancer Lett. 195 (2003) 127
2. Baserga R., Peruzzi F., and Reiss K. Int. J. Cancer 107 (2003) 873
3. Bohula E.A., Playford M.P., and Macaulay V.M. Anticancer Drugs 14 (2003) 669
4. Hartog H., Wesseling J., Boezen H.M., and van der Graaf W.T.A. Eur. J. Cancer 43 (2007) 1895
5. Sachdev D., and Yee D. Mol. Cancer Ther. 6 (2007) 1
6. Sarma P.K.S., Tandon R., Gupta P., Dastidar S.G., Ray A., Das B., and Cliffe I.A. Expert Opin. Ther. Patents 17 (2007) 25
7. Garcia-Echeverria C. IDrugs 9 (2006) 415
8. Yuan J.S.P., and Macaulay V.M. Expert Opin. Ther. Targets 12 5 (2008) 589
9. Piao W., Wang Y., Adachi Y., Yamamoto H., Li R., Imsumran A., Li H., Maehata T., Ii M., Arimura Y., Lee C.-T., Shinomura Y., Carbone D.P., and Imai K. Mol. Cancer Ther. 7 (2008) 1483
10. Maiso P., Ocio E.M., Garayoa M., Montero J.C., Hofmann F., Garcia-Echeverria C., Zimmermann J., Pandiella A., and San Miguel J.F. Br. J. Haemetol. 141 (2008) 470
11. Manara M.C., Landuzzi L., Nanni P., Nicoletti G., Zambelli D., Lollini P.L., Nanni C., Hofmann F., Garcia-Echeverria C., Picci P., and Scotlandi K. Clin. Cancer Res. 13 (2007) 1322
12. Tanno B., Mancini C., Vitali R., Mancuso M., McDowell H.P., Dominici C., and Raschella G. Clin. Cancer Res. 12 (2006) 6772
13. Scotlandi K., Manara M.C., Nicoletti G., Lollini P.-L., Lukas S., Benini S., Croci S., Perdichizzi S., Zambelli D., Serra M., Garcia-Echeverria C., Hofmann F., and Picci P. Cancer Res. 65 (2005) 3868
14. Garcia-Echeverria C., Pearson M.A., Marti A., Meyer T., Mestan J., Zimmerman J., Gao J., Brueggen J., Capraro H.-G., Cozens R., Evans D.B., Fabbro D., Furet P., Porta D.G., Liebetanz J., Martiny-Baron G., Ruetz S., and Hofmann F. Cancer Cell 5 (2004) 231
15. Mitsiades C.S., Mitsiades N.S., McMullan C.J., Poulaki V., Shringarpure R., Akiyama M., Hideshima T., Chauhan D., Joseph M., Libermann T.A., Garcia-Echeverria C., Pearson M.A., Hofmann F., Anderson K.C., and Kung A.L. Cancer Cell 5 (2004) 221
16. Haluska P., Carboni J.M., Loegering D.A., Lee F.Y., Wittman M., Saulnier M.G., Frennesson D.B., Kalli K.R., Conover C.A., Attar R.M., Kaufmann S.H., Gottardis M., and Erlichman C. Cancer Res. 66 (2006) 362
17. Zimmermann K., Wittman M.D., Saulnier M.G., Velaparthi U., Langley D.R., Sang X., Frennesson D., Carboni J., Li A., Greer A., Gottardis M., Attar R.M., Yang Z., Balimane P., Discenza L.N., and Vyas D. Bioorg. Med. Chem. Lett. 18 (2008) 4075
18. Wittman M., Carboni J., Attar R., Balasubramanian B., Balimane P., Brassil P., Beaulieu F., Chang C., Clarke W., Dell J., Eummer J., Frennesson D., Gottardis M., Greer A., Hansel S., Hurlburt W., Jacobson B., Krishnananthan S., Lee F.Y., Li A., Lin T.-A., Liu P., Ouellet C., Sang X., Saulnier M.G., Stoffan K., Sun Y., Velaparthi U., Wong H., Yang Z., Zimmermann K., Zoeckler M., and Vyas D. J. Med. Chem. 48 (2005) 5639
19. Ji Q.-S., Mulvihill M.J., Rosenfeld-Franklin M., Cooke A., Feng L., Mak G., O'Connor M., Yao Y., Pirritt C., Buck E., Eyzaguirre A., Arnold L.D., Gibson N.W., and Pachter J.A. Mol. Cancer Ther. 6 (2007) 2158
20. Rosenfeld-Franklin, M.; Cooke, A.; Pirritt, C.; Landfair, D.; Silva, S.; Turton, R.; Feng, L.; Mulvihill, M. J.; Buck, E.; Pachter, J. A.; Ji, Q.-S.; Wild, R. Abstract of Papers, AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, San Francisco, CA; American Association for Cancer Research: Philadelphia, PA, National Cancer Institute: Bethesda, MD, and European Organisation for Research and Treatment of Cancer: Brussels, Belgium, 2007; Abstract B244.
21. 2; QPC, Hopkinton, MA) and 0.5 nM activated enzyme. Reactions were stopped after 1 h at room temperature with 33 μM EDTA. Peptide phosphorylation was measured by time resolved fluorescence with 7 nM streptavidin-Surelight™ allophycocyanin (Perkin-Elmer, Waltham, MA) and 1 nM Europium-conjugated phospho-tyrosine antibodies (Perkin-Elmer). Plates were read in a Victor X5 or Viewlux 1430 ultra HTS microplate imager (Perkin-Elmer).
22. 50 values were determined from inhibition curves using XLfit4 software (Guildford, UK).
23. Girdler F., Gascoigne K.E., Eyers P.A., Hartmuth S., Crafter C., Foote K.M., Keen N.J., and Taylor S.S. J. Cell Sci. 119 (2006) 3664
24. Carvajal R.D., Tse A., and Schwartz G.K. Clin. Cancer Res. 12 (2006) 6869
25. Keen N., and Taylor S. Nat. Rev. Cancer 4 (2004) 927
26. Low dose mouse PK studies were conducted with a 1% DMSO, 10% solution in water formulation. Composite sampling was used with three mice per time point. AUC was determined from 0 to 6 h.
27. Swern D., Mancuso A.J., and Huang S. J. Org. Chem. 43 (1978) 2480
28. Nose A., and Kudo T. Chem. Pharm. Bull. 29 (1981) 1159
29. Avdeef A. Curr. Top. Med. Chem. 1 (2001) 271
30. Other kinases were screened using conditions and assays optimized for each.
31. 50 values using the Cheng-Prusoff relationship for ATP competitive inhibition.
32. IR protein was expressed and purified as previously described (Li, S.; Covino, N. D.; Stein, E. G.; Till, J. H.; Hubbard, S. R. J. Biol. Chem. 2003, 278, 26007). Protein at 10 mg/ml was complexed with a 3-fold molar excess of inhibitor for 1 h prior to crystallization. Crystals were grown by hanging drop vapor diffusion at 22° from 0.1 M MOPS, pH 7.0, 1.0 M trisodium citrate. Crystals were flash frozen in PFO prior to data collection. The structure was solved by molecular replacement using PDB:1P14 as a starting model.
33. Liu Y., and Gray N.S. Nat. Chem. Biol. 2 (2006) 358
34. Wood E.R., Truesdale A.R., McDonald O.B., Yuan D., Hassell A., Dickerson S.H., Ellis B., Pennisi C., Horne E., Lackey K., Alligood K., Rusnak D.W., Gilmer T.M., and Shewchuk L. Cancer Res. 64 (2004) 6652
35. 50 values were determined from using a 4-parameter curve fit software package (XLfit4).
36. ® in saline (IV) or water (PO). The PO study in dogs was run as a partial suspension. IV doses ranged from 0.6 to 1.3 mg/kg, and PO doses ranged from 2.1 to 7.2 mg/kg depending on species. Rats were male Sprague-Dawleys. Dogs were male beagles. Monkeys were male cynomolgus. Reported data are for 0-24 h.
37. Lipinski C.A., Lombardo F., Dominy B.W., and Freeney P.J. Adv. Drug Deliv. Rev. 23 (1997) 3
38. Belfiore A. Curr. Pharm. Des. 13 (2007) 671
39. Denley A., Carroll J.M., Brierley G.V., Cosgrove L., Wallace J., Forbes B., and Roberts Jr. C.T. Mol. Cell Biol. 27 (2007) 3569
40. Jones H.E., Gee J.M.W., Barrow D., Tonge D., Holloway B., and Nicholson R.I. Br. J. Cancer 95 (2006) 172-180
41. Denley A., Wallace J.C., Cosgrove L.J., and Forbes B.E. Horm. Met. Res. 35 (2003) 778
42. Vella V., Pandini G., Sciacca L., Mineo R., Vigneri R., Pezzino V., and Belfiore A. J. Clin. Endocrinol. Metab. 87 (2002) 245
43. Kalli K., Falowo O.I., Bale L.K., Zschunke M.A., Roche P.C., and Conover C.A. Endocrinology 143 (2002) 3259
44. Sciacca L., Mineo R., Pandini G., Murabito A., Vigneri R., and Belfiore A. Oncogene 21 (2002) 8240
45. Pandini G., Frasca F., Mineo R., Sciacca L., Vigneri R., and Belfiore A. J. Biol. Chem. 277 (2002) 39684
46. Sciacca L., Costantino A., Pandini G., Mineo R., Frasca F., Scalia P., Sbraccia P., Goldfine I.D., Vigneri R., and Belfiore A. Oncogene 18 (1999) 2471
47. Frasca F., Pandini G., Scalia P., Sciacca L., Mineo R., Costantino A., Goldfine I.D., Belfiore A., and Vigneri R. Mol. Cell Biol. 19 (1999) 3278
48. Pandini G., Vigneri R., Costantino A., Frasca F., Ippolito A., Fujita-Yamaguchi Y., Siddle K., Goldfine I.D., and Belfiore A. Clin. Cancer Res. 5 (1999) 1935